{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:06:14Z","timestamp":1793300774786,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tedizolid, a second-generation oxazolidinone, exhibits potent in vitro activity against Gram-positive bacteria, including Nocardia species, and has a more favourable safety profile than linezolid during prolonged use. However, data on itsCSF penetration and efficacy remain scarce. We describe two cases of Nocardia farcinica brain abscess treated with tedizolid and report measured serum and cerebrospinal fluid (CSF) exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case reports<\/jats:title>\n                    <jats:p>Two patients with N. farcinica brain abscesses (MIC for tedizolid 0.75\u2005mg\/L) treated with tedizolid as part of combination therapy. Total and unbound concentrations in serum and CSF were quantified using LC-MS\/MS, and PK\/PD modelling was performed. In case 1, a 60-year-old man with idiopathic CD4 lymphocytopenia initially improved but relapsed while receiving tedizolid 200\u2005mg once daily. The unbound plasma fraction was 15.7%, and CSF exposure remained low, with a predicted fAUC0\u201324\/MIC &amp;lt;3: below the PK\/PD threshold used for staphylococcal skin infections. Tedizolid was discontinued, and the patient subsequently died. In case 2, a 72-year-old diabetic patient received 200\u2005mg twice daily. The unbound plasma fraction was higher (30.1%). PK\/PD modelling predicted a CSF fAUC0\u201324\/MIC of 7.5, exceeding the proposed efficacy threshold. The patient completed therapy successfully and remained relapse-free after 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These cases highlight moderate CSF penetration of tedizolid and substantial interpatient variability in protein binding. Direct measurement of unbound concentrations was critical for accurate PK\/PD assessment. Although higher dosing may improve central nervous system (CNS) exposure and outcomes, tedizolid should not be considered interchangeable with linezolid for CNS nocardiosis. Individualized monitoring of free plasma levels may help optimize dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag004","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:55:11Z","timestamp":1767963311000},"source":"Crossref","is-referenced-by-count":2,"title":["Optimizing Tedizolid Dosing in Cerebral Nocardiosis: Clinical Impact of Direct Unbound Concentration Measurement and Population PK Modelling in Two Cases"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8330-7224","authenticated-orcid":false,"given":"Marc-Olivier","family":"Vareil","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Centre Hospitalier de la C\u00f4te Basque , Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Bouet","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Centre Hospitalier de la C\u00f4te Basque , Bayonne ,","place":["France"]},{"name":"Service de m\u00e9decine interne, Centre Hospitalier d\u2019Arcachon , Arcachon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leyssene","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Centre Hospitalier de la C\u00f4te Basque , Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Jaouen","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Centre Hospitalier de la C\u00f4te Basque , Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Wille","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Centre Hospitalier de la C\u00f4te Basque , Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Adier","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers ,","place":["France"]},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine- Pharmacie , Poitiers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Alleman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Centre Hospitalier de la C\u00f4te Basque , Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-5888","authenticated-orcid":false,"given":"Alexia","family":"Chauzy","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers ,","place":["France"]},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine- Pharmacie , Poitiers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026102711564974200_dlag004-B1","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026102711564974200_dlag004-B2","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026102711564974200_dlag004-B3","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1038\/s41598-024-55916-7","article-title":"In vitro activity of tedizolid against 43 species of Nocardia species","volume":"14","author":"Toyokawa","year":"2024","journal-title":"Sci Rep"},{"key":"2026102711564974200_dlag004-B4","author":"European Society of Clinical Microbiology and Infectious Diseases"},{"key":"2026102711564974200_dlag004-B5","doi-asserted-by":"publisher","first-page":"ofy246","DOI":"10.1093\/ofid\/ofy246","article-title":"Correction of linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for multidrug-resistant Staphylococcus epidermidis prosthetic-joint infection","volume":"5","author":"Ferry","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026102711564974200_dlag004-B6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ijantimicag.2016.11.032","article-title":"Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report","volume":"49","author":"Matin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026102711564974200_dlag004-B7","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jiac.2022.03.020","article-title":"Long-term use of tedizolid for pulmonary nocardiosis","volume":"28","author":"Chomei","year":"2022","journal-title":"J Infect Chemother"},{"key":"2026102711564974200_dlag004-B8","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1093\/jac\/dkad299","article-title":"Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient","volume":"78","author":"Corcione","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026102711564974200_dlag004-B9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cmi.2020.12.019","article-title":"How do I manage nocardiosis?","volume":"27","author":"Margalit","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026102711564974200_dlag004-B10","doi-asserted-by":"publisher","first-page":"e257935","DOI":"10.1136\/bcr-2023-257935","article-title":"Disseminated nocardiosis with persistent neurological disease","volume":"17","author":"Stellern","year":"2024","journal-title":"BMJ Case Rep"},{"key":"2026102711564974200_dlag004-B11","doi-asserted-by":"publisher","first-page":"dlaf100","DOI":"10.1093\/jacamr\/dlaf100","article-title":"Insufficient cerebrospinal fluid penetration of tedizolid: a case report","volume":"7","author":"Brousse","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"2026102711564974200_dlag004-B12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"2026102711564974200_dlag004-B13","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/cid\/cit615","article-title":"Use of pharmacokinetic\/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate","volume":"58 Suppl 1","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026102711564974200_dlag004-B14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jchromb.2015.12.056","article-title":"Simultaneous determination of tedizolid and linezolid in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study","volume":"1011","author":"Yu","year":"2016","journal-title":"J Chromatogr B"},{"key":"2026102711564974200_dlag004-B15","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026102711564974200_dlag004-B16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2146\/ajhp130482","article-title":"Tedizolid: a new oxazolidinone antimicrobial","volume":"71","author":"Kisgen","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"2026102711564974200_dlag004-B17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10928-013-9301-9","article-title":"Utility of CSF in translational neuroscience","volume":"40","author":"de Lange","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026102711564974200_dlag004-B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0009-8981(01)00573-3","article-title":"Dynamics of brain-derived proteins in cerebrospinal fluid","volume":"310","author":"Reiber","year":"2001","journal-title":"Clin Chim Acta"},{"key":"2026102711564974200_dlag004-B19","doi-asserted-by":"publisher","first-page":"104420","DOI":"10.1016\/j.yrtph.2019.104420","article-title":"Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid","volume":"107","author":"Gu","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"2026102711564974200_dlag004-B20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1124\/dmd.108.024125","article-title":"Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid","volume":"37","author":"Liu","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlag004\/66622197\/dlag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlag004\/66622197\/dlag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:56:53Z","timestamp":1793116613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag004\/8444314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag004","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"dlag004"}}